PYXS

Pyxis Oncology, Inc. [PYXS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PYXS Stock Summary

Top PYXS Correlated Resources

PYXS


Top 10 Correlated ETFs

PYXS


Top 10 Correlated Stocks

PYXS


In the News

06:00 04 Mar 2024 PYXS

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.

11:17 04 Mar 2024 PYXS

Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

04:01 04 Mar 2024 PYXS

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a company overview at the BTIG Virtual Biotechnology Conference on August 7, 2023 at 3:00 PM EST. The Pyxis Oncology management team will also host investor meetings that same day. To join the conference, email info@btig.com.

01:32 04 Mar 2024 PYXS

Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

02:59 04 Mar 2024 PYXS

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product candidates, PYX-201 and PYX-106, are currently in Phase 1 clinical trials, with promising preclinical results and unique targeting mechanisms. Pyxis Oncology presents a 'Buy' opportunity for high-risk-tolerant investors, but investors should monitor the progress of ongoing Phase 1 trials and the competitive landscape.

10:45 04 Mar 2024 PYXS

Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates

Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for challenging cancer therapies.

01:03 04 Mar 2024 PYXS

3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode

Penny stocks to watch as sympathy momentum puts focus on stocks under $5 today. The post 3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 04 Mar 2024 PYXS

Why Am I Losing Money With Penny Stocks? 3 Reasons

Use these tips to avoid losing money with penny stocks The post Why Am I Losing Money With Penny Stocks? 3 Reasons  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 04 Mar 2024 PYXS

Beginner Penny Stocks Trading Mistakes: 3 to Avoid

Are you making these penny stocks trading mistakes? The post Beginner Penny Stocks Trading Mistakes: 3 to Avoid  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:32 04 Mar 2024 PYXS

Pyxis Oncology: Cashed Up And Entering The Clinic

PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 study of PYX-106 in Q2'23, which could add additional readouts to the 2024 calendar.

PYXS Financial details

Company Rating
Neutral
Market Cap
291.9M
Income
-33.6M
Revenue
0
Book val./share
3.34
Cash/share
3.22
Dividend
-
Dividend %
-
Employees
67
Optionable
No
Shortable
Yes
Earnings
22 Mar 2024
P/E
-2.63
Forward P/E
-3.26
PEG
0.29
P/S
-
P/B
0.64
P/C
2.04
P/FCF
-1.16
Quick Ratio
4.69
Current Ratio
4.91
Debt / Equity
0.16
LT Debt / Equity
0.15
-
-
EPS (TTM)
-0.78
EPS next Y
-2.02
EPS next Q
1.58
EPS this Y
-62.81%
EPS next Y
158.97%
EPS next 5Y
158.97%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
36.59%
-
-
-
-
SMA20
51.1%
SMA50
203.87%
SMA100
177.78%
Inst Own
9.96%
Inst Trans
0.37%
ROA
-18%
ROE
-23%
ROC
-0.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
44.29M
Shs Float
30.41M
-
-
-
-
Target Price
-
52W Range
1.35-6.92
52W High
+9.67%
52W Low
+558%
RSI
76.25
Rel Volume
0.99
Avg Volume
649.78K
Volume
641.3K
Perf Week
45.9%
Perf Month
203.23%
Perf Quarter
208.92%
Perf Half Y
211.85%
-
-
-
-
Beta
1.275
-
-
Volatility
0.81%, 1.1%
Prev Close
3.46%
Price
6.58
Change
1.23%

PYXS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-0.12-0.58-9.6-3.57
Operating cash flow per share
-0.1-0.46-4.16-2.7
Free cash flow per share
-0.1-0.52-4.22-2.9
Cash per share
0.90.3732.355.43
Book value per share
-0.13-0.7130.774.87
Tangible book value per share
-0.13-0.7130.774.87
Share holders equity per share
-0.13-0.7130.774.87
Interest debt per share
00.040.020.49
Market cap
290.07M292.07M93.17M44.26M
Enterprise value
270.4M284.77M-181.4M-116.11M
P/E ratio
-108.85-22.89-1.14-0.38
Price to sales ratio
0000
POCF ratio
-129.56-28.96-2.64-0.5
PFCF ratio
-129.56-25.25-2.6-0.46
P/B Ratio
-100.93-18.670.360.28
PTB ratio
-100.93-18.670.360.28
EV to sales
0000
Enterprise value over EBITDA
-93.92-22.922.860.94
EV to operating cash flow
-120.77-28.245.131.3
EV to free cash flow
-120.77-24.625.061.21
Earnings yield
-0.01-0.04-0.88-2.66
Free cash flow yield
-0.01-0.04-0.38-2.16
Debt to equity
-0.01-0.0500.12
Debt to assets
00.0800.09
Net debt to EBITDA
6.830.594.321.3
Current ratio
26.882.214.95.9
Interest coverage
00044.67
Income quality
0.810.790.460.74
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
00.150.020.07
Capex to revenue
0000
Capex to depreciation
0-3.16-0.83-9.03
Stock based compensation to revenue
0000
Graham number
0.63.0381.5219.78
ROIC
0.970.91-0.29-0.61
Return on tangible assets
-0.13-1.26-0.29-0.56
Graham Net
-0.14-0.830.143.92
Working capital
18.97M4.41M259.97M154.98M
Tangible asset value
-2.87M-15.65M261.31M160.82M
Net current asset value
-2.98M-17.69M259.97M136.06M
Invested capital
-0.01-0.0500.12
Average receivables
000299K
Average payables
0784K6.51M9.52M
Average inventory
000437K
Days sales outstanding
0000
Days payables outstanding
0885.373.49K1.41K
Days of inventory on hand
000173.75
Receivables turnover
0000
Payables turnover
00.410.10.26
Inventory turnover
0002.1
ROE
0.930.82-0.31-0.73
Capex per share
0-0.07-0.06-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.830.69-0.5-0.41-0.56
Operating cash flow per share
-0.63-0.53-0.76-0.29-0.43
Free cash flow per share
-0.76-0.58-0.88-0.35-0.43
Cash per share
6.15.434.223.723.22
Book value per share
5.84.874.33.783.34
Tangible book value per share
5.84.874.33.782.8
Share holders equity per share
5.84.874.33.783.34
Interest debt per share
0.52-1.210.520.550.52
Market cap
64.15M44.26M141.76M98.28M82.25M
Enterprise value
-118.34M-116.11M108.95M93.64M89.15M
P/E ratio
-0.590.48-2.02-1.55-0.89
Price to sales ratio
00000
POCF ratio
-3.12-2.55-5.28-8.91-4.68
PFCF ratio
-2.58-2.3-4.54-7.39-4.66
P/B Ratio
0.340.280.930.680.6
PTB ratio
0.340.280.930.680.6
EV to sales
00000
Enterprise value over EBITDA
4.23.07-5.25-5.32-3.52
EV to operating cash flow
5.766.68-4.06-8.49-5.07
EV to free cash flow
4.776.03-3.49-7.05-5.05
Earnings yield
-0.420.52-0.12-0.16-0.28
Free cash flow yield
-0.39-0.43-0.22-0.14-0.21
Debt to equity
0.090.120.130.150.16
Debt to assets
0.070.090.110.120.12
Net debt to EBITDA
6.474.241.580.26-0.27
Current ratio
10.625.913.4616.184.91
Interest coverage
-39.490.6412.2500
Income quality
0.740.481.390.690.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000.12
Capex to operating cash flow
0.210.110.160.20
Capex to revenue
00000
Capex to depreciation
-21.33-9.68-23.19-4.31-0.12
Stock based compensation to revenue
00000
Graham number
10.398.716.935.946.47
ROIC
-0.130.12-0.1-0.09-0.14
Return on tangible assets
-0.120.11-0.1-0.09-0.14
Graham Net
5.024.013.362.942.04
Working capital
183.71M154.98M144.58M140.08M110.76M
Tangible asset value
188.75M160.82M152.16M145.28M115.65M
Net current asset value
167.66M136.06M125.54M119.35M90.35M
Invested capital
0.090.120.130.150.16
Average receivables
0299K299K00
Average payables
6.66M6.3M5.56M2.67M2.31M
Average inventory
03.17M3.17M00
Days sales outstanding
00000
Days payables outstanding
977.931.38K1.08K168.03440.03
Days of inventory on hand
01.23K000
Receivables turnover
00000
Payables turnover
0.090.070.080.540.2
Inventory turnover
00.07000
ROE
-0.140.14-0.12-0.11-0.17
Capex per share
-0.13-0.06-0.12-0.060

PYXS Frequently Asked Questions

What is Pyxis Oncology, Inc. stock symbol ?

Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS

What is Pyxis Oncology, Inc. stock quote today ?

Pyxis Oncology, Inc. stock price is $6.58 today.

Is Pyxis Oncology, Inc. stock public?

Yes, Pyxis Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap